NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
Dec 6, 2013
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma KRd Multiple myeloma is a blood cancer...
Dec 23, 2012
NCT01754402: Phase 1 / 2 - Bendamustine + Pomalidomide + Dex in Relapsed Multiple Myeloma
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: ...
Dec 21, 2012
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by...
Dec 13, 2012
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01592370: Phase 1/2: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in...
Dec 8, 2012
NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
The OPTIMISMM trial The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose...
Dec 6, 2012
NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
SWOG 1211 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed...
Dec 6, 2012
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease NCT01410500:...
Dec 16, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
Dec 9, 2011
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
EMN European Myeloma Network NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma...
Dec 7, 2011
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors,...
Dec 3, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib...
Dec 1, 2011
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry The purpose of the Connect® MM Registry is to explore the natural history...
Dec 18, 2010
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
The EMN02/HOVON95 trial (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Study to Compare VMP With HDM Followed by VRD...
Dec 18, 2010
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
EMN01 European Myeloma Network Newly Diagnosed Multiple Myeloma NCT01093196: Phase 3: Len and Dex Vs Melphalan Prednisone and Len Vs...
Dec 16, 2010
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
Dec 11, 2010
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
ECOG E3A06 ECOG-ACRIN Cancer Research Group ECOG E3A06 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk...
Dec 10, 2010
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
EMN - European Myeloma Network Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus...
Dec 3, 2010
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
Dec 30, 2008